心肌病基因罕见变异与癌症治疗诱发的心肌病相关
研究纳入213例癌症治疗诱发心肌病(CCM)患者,对心肌病相关基因(含9个预设基因)进行测序,并与癌症基因组图谱参与者、健康志愿者及 ancestry-matched 参考人群比较罕见变异频率。结果显示CCM患者罕见蛋白改变变异富集,以TTN截短变异(TTNtv)为主,TTNtv携带者心衰、房颤及心肌恢复不良更多;蒽环类处理的TTNtv小鼠和心肌细胞显示持续收缩功能障碍。
要点
- CCM患者中TTN截短变异占7.5%,显著高于癌症基因组图谱参与者的1.1%。
- 携带TTNtv的成人CCM患者心衰和房颤更多、心肌恢复更差。
- 基因型结合累积化疗剂量和传统心血管危险因素可改善高危患者识别。
核心结论
- 心肌病相关基因(尤其TTNtv)的未识别罕见变异增加儿童和成人CCM风险,并与成人心血管不良事件相关。
研究设计与样本
- 研究纳入213例CCM患者,来自3个队列:回顾性招募的99例多样癌症成人、前瞻性表型分析的73例乳腺癌成人、前瞻性表型分析的41例急性髓系白血病儿童。
- 对心肌病基因(包括9个预设基因)进行测序,并将罕见变异患病率与癌症基因组图谱参与者(n=2053)、健康志愿者(n=445)及 ancestry-matched 参考人群比较。
- 按基因型分层评估临床特征和结局,并在蒽环类处理的TTNtv小鼠中建模。
主要发现
- CCM在化疗后0.4至9年诊断,90%患者接受蒽环类药物。
- 在9个优先基因中,CCM患者罕见蛋白改变变异多于比较队列(P≤1.98e-04)。
- TTNtv在CCM患者中占7.5%,高于癌症基因组图谱参与者的1.1%(P=7.36e-08)、健康志愿者的0.7%(P=3.42e-06)和参考人群的0.6%(P=5.87e-14)。
- 携带TTNtv的成人CCM患者心衰和房颤更多(P=0.003)、心肌恢复受损(P=0.03)。
- 蒽环类处理的TTNtv小鼠和分离的TTNtv心肌细胞显示持续收缩功能障碍,与野生型不同(P=0.0004和P<0.002)。
临床怎么用
- 对癌症患者进行心肌病相关基因(尤其TTN)检测可能有助于识别CCM高危个体。
- 基因型信息可与累积化疗剂量和传统心血管危险因素结合用于风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cancer therapy-induced cardiomyopathy (CCM) is associated with cumulative drug exposures and preexisting cardiovascular disorders. These parameters incompletely account for substantial interindividual susceptibility to CCM. We hypothesized that rare variants in cardiomyopathy genes contribute to CCM. METHODS: We studied 213 patients with CCM from 3 cohorts: retrospectively recruited adults with diverse cancers (n=99), prospectively phenotyped adults with breast cancer (n=73), and prospectively phenotyped children with acute myeloid leukemia (n=41). Cardiomyopathy genes, including 9 prespecified genes, were sequenced. The prevalence of rare variants was compared between CCM cohorts and The Cancer Genome Atlas participants (n=2053), healthy volunteers (n=445), and an ancestry-matched reference population. Clinical characteristics and outcomes were assessed and stratified by genotypes. A prevalent CCM genotype was modeled in anthracycline-treated mice. RESULTS: CCM was diagnosed 0.4 to 9 years after chemotherapy; 90% of these patients received anthracyclines. Adult patients with CCM had cardiovascular risk factors similar to the US population. Among 9 prioritized genes, patients with CCM had more rare protein-altering variants than comparative cohorts ( P≤1.98e-04). Titin-truncating variants (TTNtvs) predominated, occurring in 7.5% of patients with CCM versus 1.1% of The Cancer Genome Atlas participants ( P=7.36e-08), 0.7% of healthy volunteers ( P=3.42e-06), and 0.6% of the reference population ( P=5.87e-14). Adult patients who had CCM with TTNtvs experienced more heart failure and atrial fibrillation ( P=0.003) and impaired myocardial recovery ( P=0.03) than those without. Consistent with human data, anthracycline-treated TTNtv mice and isolated TTNtv cardiomyocytes showed sustained contractile dysfunction unlike wild-type ( P=0.0004 and P<0.002, respectively). CONCLUSIONS: Unrecognized rare variants in cardiomyopathy-associated genes, particularly TTNtvs, increased the risk for CCM in children and adults, and adverse cardiac events in adults. Genotype, along with cumulative chemotherapy dosage and traditional cardiovascular risk factors, improves the identification of patients who have cancer at highest risk for CCM. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifiers: NCT01173341; AAML1031; NCT01371981.
引用
- Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA, et al. Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy. Circulation. 2019. PMID: 30987448. doi:10.1161/CIRCULATIONAHA.118.037934
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。